Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617194 | 1.00 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1MAPK1MAPTMEN1 | |
| SCHEMBL14907130 | 0.88 | SMN1; SMN2 (0.86) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29921207 | 0.85 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL7370339 | 0.85 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL9016652 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MAPK1MAPTMEN1 | |
| SCHEMBL11832759 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MAPK1MAPTMEN1 | |
| SCHEMBL10913744 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1MAPK1MAPTMEN1 | |
| SCHEMBL11856611 | 0.79 | MAPT (0.55) | SMN1; SMN2ALDH1A1MAPK1MAPTMEN1 | |
| SCHEMBL17782662 | 0.78 | KDM4E (0.53) | SMN1; SMN2ALDH1A1MAPK1MAPTMEN1 | |
| SCHEMBL20749465 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPK1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304588-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-116981458-A | Compounds with tetrahydroindole-1-carboxamides as BCL-2 inhibitors | 伊尔治疗学股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023160509-A1 | AMIDINE DERIVATIVE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-08-31 | — | — | WO | disclosed |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4154884-A1 | ANTI-SARS-COV-2 DURG | Oncolys BioPharma, Inc. (JP) | 2023-03-29 | — | — | EP | disclosed |
| US-20220289745-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | EIL TERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| US-10662173-B2 | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-26 | — | — | US | disclosed |
| US-20120316342-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | ONCOLYS BIOPHARMA, INC. (JP) | 2012-12-13 | — | — | US | disclosed |
| EP-2532652-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | Kagoshima University (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-6620807-B1 | Temporary delay of urination for treatment of diabetes, urinary incontinence, bleeding or coagulation disorders | WYETH | 2003-09-16 | — | — | US | disclosed |
| EP-1149104-B1 | PYRROLOBENZODIAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | WYETH CORP (US) | 2002-12-11 | — | — | EP | disclosed |
| CN-1339035-A | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists | AMERICAN HOME PROD (US) | 2002-03-06 | — | — | CN | disclosed |
| US-6344451-B1 | DIABETES INSIPIDUS, NOCTURNAL ENURESIS, NOCTURIA, URINARY INCONTINENCE, BLEEDING AND COAGULATION DISORDERS, OR TEMPORARY DELAY OF URINATION | AMERICAN HOME PRODUCTS | 2002-02-05 | — | — | US | disclosed |
| EP-1149097-A2 | PYRIDOBENZODIAZEPINE AND PYRIDOBENZOXAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1149104-A2 | PYRROLOBENZODIAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000046225-A2 | PYRIDOBENZODIAZEPINE AND PYRIDOBENZOXAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-10 | — | — | WO | disclosed |
| WO-2000046228-A2 | PYRROLOBENZODIAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662173-B2 | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | RB1, IDO1, BCL2A1 | SMN1; SMN2 3448/4885ALDH1A1 1103/4885MAPK1 2938/4885 |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, SARS1 | SMN1; SMN2 4289/4885ALDH1A1 3243/4885MAPK1 855/4885 |
| US-20220289745-A1 | COMPOUNDS HAVING TETRAHYDROINDOLIZINE-1-CARBOXAMIDE AS BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2A1 | SMN1; SMN2 2191/4885ALDH1A1 758/4885MAPK1 1950/4885 |
| US-11697650-B2 | Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors | BCL2, BCL2L1, BCL2A1 | SMN1; SMN2 2191/4885ALDH1A1 758/4885MAPK1 1950/4885 |
| US-20120316342-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | HAVCR2, SLC10A1, FABP1 | SMN1; SMN2 4017/4885ALDH1A1 251/4885MAPK1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.